BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Clinical trial NCT00949650 · COMPLETED

Trial details

NCT number: NCT00949650
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Adenocarcinoma

Start date: 2009-08-14
Primary completion: 2012-02-09
Enrollment: 345

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.